SCHEMBL1768686

SCHEMBL1768686

CCOc1ccc(C=CC(=O)OC(C)C)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.67
AKR1B10 O60218 1/20 0.67
CA1 P00915 1/20 0.67
CA2 P00918 1/20 0.67
AKR1B1 P15121 1/20 0.67
CA7 P43166 1/20 0.67
CA9 Q16790 1/20 0.67
CA14 Q9ULX7 1/20 0.67
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
MAPT P10636 4/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
KDM4E B2RXH2 3/20 0.58
ALDH1A1 P00352 2/20 0.58
KMT2A Q03164 2/20 0.58
HTT P42858 1/20 0.58
MAOB P27338 9/20 0.57
ABCG2 Q9UNQ0 1/20 0.57
TP53 P04637 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19244409 1.00 CA12 (0.67) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL19244370 0.90 CA12 (0.61) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL28155071 0.90 CA12 (0.61) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL19244430 0.90 CA12 (0.61) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL27472645 0.88 TAS1R3 (0.59) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL19244201 0.88 TAS1R3 (0.63) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL19244202 0.88 TAS1R3 (0.63) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL14117363 0.85 CA12 (0.60) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL342878 0.84 CA12 (0.71) CA12AKR1B10CA1CA2AKR1B1
SCHEMBL2775098 0.84 MAOB (0.64) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133665-A1 OIL-IN-WATER EMULSION L V M H RECHERCHE (FR) 2025-06-26 WO disclosed
CN-114746064-B Dual phase sunscreen composition 莱雅公司 2025-05-06 CN disclosed
CN-114760974-B Powdery cosmetic composition 莱雅公司 2025-04-29 CN disclosed
EP-4452208-A1 AQUEOUS EMULSION L V M H RECHERCHE (FR) 2024-10-30 EP disclosed
CN-118510486-A Aqueous emulsion LVMH研究公司 2024-08-16 CN disclosed
CN-117597102-A Sun protection W/O emulsion 莱雅公司 2024-02-23 CN disclosed
WO-2023118912-A1 AQUEOUS EMULSION L V M H RECHERCHE (FR) 2023-06-29 WO disclosed
US-20230040911-A1 Oil-In-Water-Type Emulsion Cosmetic L V M H RECHERCHE (FR) 2023-02-09 US disclosed
US-20230025603-A1 SUN CARE COMPOSITION L'OREAL (FR) 2023-01-26 US disclosed
WO-2023277194-A1 SUNSCREEN W/O EMULSION L'OREAL (FR) 2023-01-05 WO disclosed
US-20170242174-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME TOSOH CORPORATION (JP) 2017-08-24 US disclosed
EP-3208301-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME Tosoh Corporation (JP) 2017-08-23 EP disclosed
WO-2017110152-A1 HIGH INTERNAL PHASE EMULSION COMPOSITION FOR IMPROVING ITS SPF AND RHEOLOGY L'OREAL (FR) 2017-06-29 WO disclosed
CN-106795327-A Resin composition and optical compensation film using the same 东曹株式会社 2017-05-31 CN disclosed
US-20150272897-A1 COACERVATION ENCAPSULATION METHOD THAT DOES NOT INVOLVE THE USE OF TOXIC CROSS-LINKING AGENTS SEPPIC SA (FR) 2015-10-01 US disclosed
CN-104703686-A Coacervation encapsulation method that does not involve use of toxic cross-linking agents SEPPIC SA 2015-06-10 CN disclosed
EP-2688650-A1 FILM-FORMING COMPOSITION CONTAINING A SUN FILTER, AND USE THEREOF FOR THE TREATMENT OF SCARS Laboratoires Urgo (FR) 2014-01-29 EP disclosed
WO-2012131237-A1 FILM-FORMING COMPOSITION CONTAINING A SUN FILTER, AND USE THEREOF FOR THE TREATMENT OF SCARS LABORATOIRES URGO (FR) 2012-10-04 WO disclosed
EP-2501359-A1 A COSMETIC OR DERMATOLOGICAL COMPOSITION WITH LOW STICKINESS, CONTAINING A LIPOPHILIC ACTIVE INGREDIENT L'Oréal (FR) 2012-09-26 EP disclosed
WO-2011061864-A1 A COSMETIC OR DERMATOLOGICAL COMPOSITION WITH LOW STICKINESS, CONTAINING A LIPOPHILIC ACTIVE INGREDIENT L'OREAL (FR) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040911-A1 Oil-In-Water-Type Emulsion Cosmetic CUTA, PHOSPHO1, LIPE CA12 1654/4885AKR1B10 3453/4885CA1 3906/4885
US-20150272897-A1 COACERVATION ENCAPSULATION METHOD THAT DOES NOT INVOLVE THE USE OF TOXIC CROSS-LINKING AGENTS LIPA, MTCL3, LRAT CA12 774/4885AKR1B10 2975/4885CA1 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.